What’s new

• Dugar family launches mandatory open offer for up to 26% at ₹54/share, valued at ₹3.54 cr.
• Separate SPA to acquire 34.56% from promoter at ₹50/share for ₹4.35 cr.
• Combined transaction at ₹7.89 cr is over half of Colinz's ₹15 cr market cap.

Why it matters

This is a change-of-control event for a nano-cap pharma company. The acquirers, who already held 15.01%, could end up with up to 75.56% post-offer. For a stock with a market cap of just ₹15 crore, the control premium and mandatory offer signal a major shift in ownership and direction.

What we’re watching

• Subscription to the open offer: will existing shareholders tender at ₹54?
• Delisting prospects: combined stake could cross the 75% threshold.
• Strategic plans: the Dugar family has not yet disclosed their roadmap for Colinz.

The full read

The Dugar family is buying control of Colinz Laboratories in a two-step transaction. First, a share purchase agreement to acquire 34.56% from promoter Vijaya Mani at ₹50/share for ₹4.35 crore. Then a mandatory open offer for up to 26% at ₹54/share, worth ₹3.54 crore. The combined ₹7.89 crore deal is over half of Colinz's ₹15 crore market cap. The acquirers, Annjana, Likhitta, Antariksh Dugar, and PAC Padam Dugar, held 15.01% before. Post-closing, they could own up to 75.56%. It is a clear change in control. For a nano-cap pharma stock with a trailing P/E of 29.5 and ROE of just 5.2%, the control premium attached to this transaction is substantial relative to its market cap. The open question is what the Dugar family plans to do with a near-76% holding.

Primary source: BSE · NSE